- Home
- NRO vs CHRS Comparison
NRO vs CHRS Comparison
Compare NRO & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- CHRS
- Stock Information
- Founded
- NRO 2003
- CHRS 2010
- Country
- NRO United States
- CHRS United States
- Employees
- NRO N/A
- CHRS N/A
- Industry
- NRO Finance/Investors Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRO Finance
- CHRS Health Care
- Exchange
- NRO Nasdaq
- CHRS Nasdaq
- Market Cap
- NRO 199.6M
- CHRS 194.1M
- IPO Year
- NRO N/A
- CHRS 2014
- Fundamental
- Price
- NRO $3.20
- CHRS $1.73
- Analyst Decision
- NRO
- CHRS Strong Buy
- Analyst Count
- NRO 0
- CHRS 4
- Target Price
- NRO N/A
- CHRS $4.51
- AVG Volume (30 Days)
- NRO 239.4K
- CHRS 1.4M
- Earning Date
- NRO 01-01-0001
- CHRS 11-05-2025
- Dividend Yield
- NRO 11.41%
- CHRS N/A
- EPS Growth
- NRO N/A
- CHRS N/A
- EPS
- NRO N/A
- CHRS 1.55
- Revenue
- NRO N/A
- CHRS $272,209,000.00
- Revenue This Year
- NRO N/A
- CHRS N/A
- Revenue Next Year
- NRO N/A
- CHRS $109.48
- P/E Ratio
- NRO N/A
- CHRS $1.11
- Revenue Growth
- NRO N/A
- CHRS 52.33
- 52 Week Low
- NRO $2.51
- CHRS $0.66
- 52 Week High
- NRO $3.45
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- NRO 46.21
- CHRS 62.87
- Support Level
- NRO $3.19
- CHRS $1.63
- Resistance Level
- NRO $3.25
- CHRS $1.89
- Average True Range (ATR)
- NRO 0.04
- CHRS 0.12
- MACD
- NRO -0.01
- CHRS -0.01
- Stochastic Oscillator
- NRO 38.46
- CHRS 67.75
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.